ACE-031 — Research Overview
Chemical Name: Activin Receptor Type IIB — IgG1-Fc Fusion Protein Also Known As: Ramatercept, ActRIIB-Fc Developer: Acceleron Pharma Target: Activin receptor type IIB ligands including myostatin (GDF-8), GDF-11, and activin A Category: Soluble decoy receptor fusion protein / myostatin inhibitor
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is ACE-031?
ACE-031 is a recombinant fusion protein engineered by combining the extracellular domain of the human activin receptor type IIB with the Fc portion of human IgG1. Rather than activating a biological pathway ACE-031 functions as a decoy receptor. It circulates freely and intercepts the same ligands that would normally activate the native ActRIIB receptor on muscle cells, neutralizing them before they can signal.
The primary ligands captured by ACE-031 include myostatin (GDF-8), GDF-11, and activin A — all members of the transforming growth factor-beta superfamily and all known negative regulators of skeletal muscle mass. By neutralizing these inhibitory signals ACE-031 removes a key brake on muscle growth, bone formation, and metabolic regulation in preclinical and clinical research models.
ACE-031 has been studied in both animal models and human clinical trials, making it one of the more clinically advanced compounds in the myostatin inhibition research space. Clinical development was discontinued in 2013 due to vascular adverse events, though the biological data gathered across Phase 1 and Phase 2 trials remains scientifically significant and is frequently cited in ongoing muscle-wasting and sarcopenia research literature.
Mechanism of Action
Myostatin, also known as growth differentiation factor-8 (GDF-8), is a protein produced by muscle cells that acts as a powerful inhibitor of both skeletal muscle hypertrophy (increase in muscle fiber size) and hyperplasia (increase in fiber number). It does this by binding to ActRIIB receptors on muscle cells and triggering downstream signaling that suppresses protein synthesis and muscle growth. This biological mechanism evolved to prevent uncontrolled muscle overgrowth but in disease and aging contexts elevated myostatin is associated with accelerated muscle wasting.
ACE-031 intercepts myostatin and related ligands in circulation before they can reach their native receptors. A key distinction from earlier myostatin-specific antibodies is that because ACE-031 targets the ActRIIB receptor broadly rather than myostatin alone it captures multiple inhibitory ligands simultaneously, producing broader and larger effects on muscle mass than single-target myostatin inhibition in published research.
Downstream effects observed across preclinical and clinical research include the following.
Removal of inhibitory signaling allows for greater protein synthesis and muscle fiber development.
Muscle fiber cross-sectional area increases in both type I slow-twitch and type II fast-twitch fibers.
Lean body mass increases independent of exercise stimulus.
Bone formation biomarkers rise, suggesting increased osteoblast activity alongside muscle effects.
Fat mass and associated metabolic biomarkers shift favorably.
Force-generating capacity of muscle tissue improves in animal models.
Published Research
Study 1 — Phase 1 Human Clinical Trial: Single Ascending Dose in Healthy Volunteers
Authors: Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE et al. Year: 2013 Journal: Muscle and Nerve PMID: 23169607 Full text: https://pubmed.ncbi.nlm.nih.gov/23169607/
This was the first published human clinical trial investigating ACE-031. It was a double-blind placebo-controlled single ascending dose study conducted in 48 healthy postmenopausal women who received a single subcutaneous dose of ACE-031 ranging from 0.02 to 3 mg/kg or placebo at a 3 to 1 ratio.
ACE-031 was generally well-tolerated across the dose range studied.
Mean half-life of ACE-031 was 10 to 15 days, consistent with a long-acting biological compound.
At the 3 mg/kg dose statistically significant increases in total body lean mass of 3.3% measured by DXA and thigh muscle volume of 5.1% measured by MRI were observed at day 29.
Statistically significant changes in serum biomarkers indicated ACE-031 also improved bone formation markers and fat metabolism — a secondary finding not part of the primary trial objective.
Adverse events were mild and primarily consisted of injection site erythema.
This study established proof of concept that a single dose of ACE-031 could produce measurable statistically significant changes in lean mass and muscle volume in humans within 29 days.
Study 2 — Muscle Growth Independent of Fiber Type: Animal Model
Authors: Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL Year: 2010 Journal: Journal of Applied Physiology PMID: 20466801 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC2944638/
This preclinical study established a critical mechanistic distinction for ACE-031 — that its muscle-building effects extend across both major muscle fiber types, which had not been demonstrated with earlier myostatin-specific inhibitors. C57BL/6 mice were treated with ACE-031 at 10 mg/kg twice weekly for 4 weeks.
ACE-031-treated mice gained 16% more body weight than vehicle controls by day 25 of the study.
Wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33%, 44%, 46%, and 26% respectively.
Muscle fiber cross-sectional area increased by 22% in type I fibers and 28% in type II fibers in the soleus.
In the plantaris which is predominantly type II muscle, mean fiber cross-sectional area increased by 57%.
Muscle fiber number was unchanged confirming growth was hypertrophic rather than hyperplastic.
Fiber type distribution was not significantly altered, confirming ACE-031 promotes growth without changing the fundamental character of the muscle.
The authors concluded this was the first report showing that inhibition of negative regulators of skeletal muscle by a soluble ActRIIB decoy receptor increases muscle mass independent of fiber type, distinguishing it from selective myostatin antibodies that predominantly target type II fibers.
Study 3 — Phase 2 Clinical Trial: Duchenne Muscular Dystrophy
Authors: Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM Year: 2017 Journal: Muscle and Nerve PMID: 27462804 Full text: https://pubmed.ncbi.nlm.nih.gov/27462804/
This was the Phase 2 randomized double-blind placebo-controlled clinical trial of ACE-031 in ambulatory boys with Duchenne muscular dystrophy, one of the most severe muscle-wasting diseases affecting children. ACE-031 was administered subcutaneously every 2 to 4 weeks at ascending doses.
ACE-031 was not associated with serious or severe adverse events during the study period.
A trend toward maintenance of 6-minute walk test distance was observed in ACE-031-treated groups compared to a decline in the placebo group, though this did not reach statistical significance likely due to early study termination.
Trends for increased lean body mass, improved bone mineral density, and reduced fat mass were observed in treated subjects.
The study was stopped after the second dosing regimen by the Data Safety Monitoring Board due to safety signals of epistaxis and telangiectasias.
The vascular adverse events were attributed to off-target inhibition of BMP9 and BMP10 — growth factors that regulate vascular endothelial stability — which also bind the ActRIIB receptor.
The authors concluded that myostatin inhibition remains a promising therapeutic approach for Duchenne muscular dystrophy and that the vascular findings have directly informed the design of next-generation more selective myostatin inhibitors currently in development.
Study 4 — Bone Formation in a DMD Mouse Model
Authors: Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, Heikinheimo K, Hulmi JJ, Kiviranta R Year: 2017 Journal: BMC Musculoskeletal Disorders PMID: 28103859 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC5244551/
This study focused specifically on ACE-031’s effects on bone in a mouse model of Duchenne muscular dystrophy.
Treatment improved bone mass and bone strength in DMD model mice across both cortical and trabecular bone parameters.
The findings suggest that ActRIIB ligand blockade influences bone metabolism directly and independently of the mechanical loading changes caused by muscle mass increases.
Results support the hypothesis that the muscle-bone relationship is partially mediated through shared signaling pathways in the TGF-beta superfamily and that ActRIIB decoy receptor treatment can address both simultaneously.
Study 5 — Bone Formation Enhancement: Myostatin and Activin Decoy Receptor
Authors: Bialek P, Parkington J, Li X, Gavin D, Wallace C, Zhang J, Root A, Yan G, Warner L, Seeherman HJ, Yaworsky PJ Year: 2014 Journal: Bone, Elsevier PMID: 24333131 Full text: https://pubmed.ncbi.nlm.nih.gov/24333131/
This study examined the bone-specific effects of a myostatin and activin decoy receptor — the same class of molecule as ACE-031 — in mouse models.
Administration of the ActRIIB-based decoy receptor enhanced bone formation in treated mice across multiple skeletal sites.
The mechanism appeared to involve increased osteoblast activity rather than suppression of bone resorption, which is a distinct profile from bisphosphonate-class interventions.
The authors concluded that the ActRIIB ligand-binding approach represents a potential strategy for studying conditions of low bone mass alongside muscle-wasting research.
Current Research Status and Important Safety Context
ACE-031’s clinical development program was formally discontinued by Acceleron Pharma in 2013 following the safety findings in the DMD Phase 2 trial. The vascular adverse events — epistaxis and telangiectasias — were traced to the broad ligand-binding profile of ActRIIB, which also captures BMP9 and BMP10. These two growth factors play a critical role in maintaining vascular endothelial stability and their inhibition by ACE-031 produced the observed vascular side effects.
This finding has directly shaped subsequent research in the myostatin inhibition field, with newer compounds engineered for greater selectivity targeting myostatin or activin A specifically while sparing BMP9 and BMP10 signaling.
What remains from the ACE-031 research program is the following.
Proof-of-concept human data showing statistically significant lean mass and muscle volume increases from a single dose.
A well-characterized safety and pharmacokinetic profile from Phase 1 and Phase 2 trials.
Mechanistic insight into the dual muscle and bone effects of ActRIIB ligand blockade.
A clear understanding of the off-target vascular risk tied to broad ActRIIB inhibition.
ACE-031 is listed on the WADA 2024 Prohibited Substances List under category S4.3 due to its muscle-building properties, classifying it as a prohibited substance in competitive sport contexts.
Reconstitution Note
ACE-031 is a recombinant fusion protein. Bacteriostatic water is the standard reconstitution solvent for this class of compound in laboratory research settings. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the ACE-031 product page: https://roguecompounds.com/product/ace-031/